Drug name - Lynparza

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7151102 ASTRAZENECA Phthalazinone derivatives
Apr, 2022

(7 months ago)

US7981889 ASTRAZENECA Phthalazinone derivatives
Oct, 2024

(1 year, 10 months from now)

US7449464 ASTRAZENECA Phthalazinone derivatives
Oct, 2024

(1 year, 10 months from now)

US8247416 ASTRAZENECA Phthalazinone derivative
Sep, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9169235 ASTRAZENECA Phthalazinone derivatives
Mar, 2024

(1 year, 3 months from now)

US9566276 ASTRAZENECA Phthalazinone derivatives
Mar, 2024

(1 year, 3 months from now)

US8912187 ASTRAZENECA Phthalazinone derivatives
Mar, 2024

(1 year, 3 months from now)

US8143241 ASTRAZENECA DNA damage repair inhibitors for treatment of cancer
Aug, 2027

(4 years from now)

US8071579 ASTRAZENECA DNA damage repair inhibitors for the treatment of cancer
Aug, 2027

(4 years from now)

US8475842 ASTRAZENECA Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
Dec, 2029

(7 years from now)

US8859562 ASTRAZENECA Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Aug, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 8, 2027
New Indication (I) Mar 11, 2025

Drugs and Companies using OLAPARIB ingredient

Market Authorisation Date: 17 August, 2017

Treatment: Treatment of deleterious or suspected deleterious germline or somatic brca-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; Treatment of deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; Maintenance treatment of deleterious or suspected deleterious gbrca-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen; Treatment of deleterious or suspected deleterious germline brca-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy; Maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; Maintenance treatment of gbrca- or sbrca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy; Treatment of hr-negative, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; Treatment of hr-positive, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting, and with endocrine therapy or are inappropriate for endocrine therapy; Maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; Maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; Maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; Maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; Maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; Maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; Adjuvant treatment of patients with gbrca-mutated human epidermal growth factor receptor 2 (her2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy; Maintenance treatment of brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; Treatment of brca mutated ovarian cancer using parp inhibitor

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription
150MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.